Background A substantial genetic component accounts for Autism Spectrum Disorders (ASD) aetiology, with some rare and common genetic risk factors recently identified. Large collections of DNAs from thoroughly characterized ASD families are an essential step to confirm genetic risk factors, identify new variants and investigate genotype-phenotype correlations. The Italian Autism Network aimed at constituting a clinical database and a biorepository of samples derived from ASD subjects and first-degree relatives extensively and consistently characterized by child psychiatry centers in Italy. Methods The study was approved by the ethical committee of the University of Verona, the coordinating site, and by the local ethical committees of each recruiting site. Certified staff was specifically trained at each site for the overall study conduct, for clinical protocol administration and handling of biological material. A centralized database was developed to collect clinical assessment and medical records from each recruiting site. Children were eligible for recruitment based on the following inclusion criteria: age 4-18 years, at least one parent or legal guardian giving voluntary written consent, meeting DSM-IV criteria for Autistic Disorder or Asperger's Disorder or Pervasive Developmental Disorder NOS. Affected individuals were assessed by full psychiatric, neurological and physical examination, evaluation with ADI-R and ADOS scales, cognitive assessment with Wechsler Intelligence Scale for Children or Preschool and Primary, Leiter International Performance Scale or Griffiths Mental Developmental Scale. Additional evaluations included language assessment, the Krug Asperger's Disorder Index, and instrumental examination such as EEG and structural MRI. DNA, RNA and plasma were collected from eligible individuals and relatives. A central laboratory was established to host the biorepository, perform DNA and RNA extraction and lymphocytes immortalisation.
development for the first 6-18 months of life, followed by a period of regression in language and motor skills [5] . Both CDD and RS represent nosologically distinct disorders from AD, AS and PDD -NOS. In this manuscript, we use the term ASD to refer to AD, AS and PDD-NOS since the three diagnoses can be considered as a continuum rather than clear distinct disorders, consistently with the newly revised DSM-5. Within each of the three diagnostic categories, clinical heterogeneity is substantial. The fact that AD children share the same diagnostic categories does not imply they share set or severity of core and ASD-associated symptoms. Also, heterogeneity on ASD aetiology is more than likely. Several etiological hypotheses exist, such as altered synaptic dysfunction [6] leading to imbalanced excitatory and inhibitory neurotransmission [7] . However, a unifying aetiological theory is still lacking, and it is more than likely that the clinical heterogeneity is also paralleled by etiological heterogeneity.
Prevalence of ASD is reported to be much higher in most recent studies as compared to studies conducted a decade ago. Recent epidemiological studies indicate a worldwide prevalence for ASD ranging from 0.6 to 0.7 % with an approximate males to females ratio of 4-5 to 1 [8, 9] , as compared to the prevalence of less than 0.2 % in earlier investigations [10] . The interpretation of increased prevalence detected in recent studies is not straightforward and has raised controversial debates on the potential causes. The original paper published in Lancet [11] that initiated the controversy on vaccines as a putative cause of autism has been recently retracted by the Journal since fraud has been detected. The vast majority of the scientific community agrees on the unlikelihood of vaccination as a cause. One confounding factor, when reporting prevalence estimates, could be the change over time of diagnostic criteria for ASD, making the comparisons of epidemiological studies more difficult. It is commonly believed that the increase in the overall reported prevalence is mostly due to the development of more comprehensive ascertainment and to the expansion of diagnostic categories, which include milder forms of the disorder [12] .
Considerable evidence from twin studies indicates a substantial genetic component in the aetiology of ASD. ASD heritability has been estimated to be between 80 and 90% according to recent family and twin studies [13] . Monozygotic twin concordance has been found to as high as > 88%, whilst in dizygotic pairs and siblings the concordance rates are >30% and >15%, respectively, higher than what previously reported, suggesting a significant environmental contribution to ASD [14] .
Substantial heterogeneity also exists for the genetic component of ASD, where the interplay between commonly inherited variants (single nucleotide polymorphism or SNPs) and highly penetrant rare variations results with a complex genetic architecture [15] . A small proportion of ASD cases has been associated to de novo copy number variations (CNV), including deletions and duplications, as well as to de novo pathogenic single nucleotide variations (SNVs), accounting for a total of 3% of cases according to recent estimates [16] . Furthermore, ASD related syndromes for which the genetic cause is known account for additional 3.4% of ASD. These data support a polygenic model, where most ASD liability resides with many common variations along the genome, although the total genetic contribution to ASD (including de novo variations, syndromic mutations, non-additive and additive SNP effects) does not exceed 60%, with the remaining proportion being unaccounted for [16] . Still, the increased number of rare variants exhibiting large individual effect sizes leaves open the single major gene model, consistent with earlier estimates suggesting about 10 to 20% of ASD cases to be due to known genetic abnormalities [17] .
The most common ASD associated syndromes include: i) Fragile X syndrome (caused by expansion of polymorphic CGG repeat upstream of the FMR1 gene) in which over 40% show Autism core symptoms; ii) Angelman syndrome, determined by a deletion of 15q11-13 where ASD is present in about 50% of cases; iii) Tuberous Sclerosis, due to mutations in two functionally-related genes, TSC1 and TSC2, in which autism is present in more than 60% cases; iv) 22q deletion (or Phelan-McDermid) syndrome where about 80% of cases present with autistic symptoms [16] .
Recent sequencing approaches (including exome-or whole-genome sequencing) have contributed to the identification (or validation) of highly penetrant rare genetic variants, including CHD8, GRIN2B, SCN2A, and SYNGAP1 [18] (see also [19] for a recent review). De novo mutations associated to ASD are often located in genes functionally correlated. Among them, neuroligin 3 and 4 (NLGN3 and NLGN4), Neurexin3, SHANK3 and CNTNAP2, which are all involved in synapse formation and specialization, supporting the notion that altered synaptic formation can lead to abnormal neural pathways in ASD ) [6] . However, it is important to underline that no single neurobiological hypothesis yet can explain the aetiology of ASD, which is still elusive and likely to be determined by multiple genetic and non-genetic factors.
As far as the contribution from commonly inherited variants, the advent of affordable high-throughput genotyping technologies allowing for genome-wide association studies (GWAS), combined with the increased availability of ASD collections, is beginning to pay-off. Although limited in statistical power to robustly identify genome-wide significant loci, early studies have shown the potential of GWAS in the identification putative novel risk variants [20] . Two of the first GWAS in ASD reported the identification of common genetic variants residing between two genes mapping on the chromosome 5 and coding for cell molecule adhesion proteins (cadherin 9 and cadherin 10), providing support to a previously hypothesized altered neuronal cell adhesion in ASD [21, 21] . A third study, based on a broad collaborative effort, lead to the identification of an additional common variant on chromosome 5, adjacent to several genes including SEMA5A, a member of semaphorin protein involved in axonal guidance [23] . Later, the Autism Genome Project (AGP, The AGP Consortium, representing more than 50 centers in North America and Europe) identified genome-wide association signals for SNPs located in the gene MACROD2 [24] and CNTNAP2, a gene previously implicated in ASD [25] .
Most of the above findings were not replicated in a subsequent meta-analysis in European samples [26, 27] , suggesting the need for larger ASD cohorts to clarify the role of common variation in the disorder. Large-scale coordinated international collaborations such as the Psychiatry Genomic Consortium (PGC) have been established, with the aim of conducting statistically rigorous and comprehensive GWAS meta-analyses for major psychiatric disorders [28, 29] . The first meta-analysis of the ASD Working Group of the Psychiatric Genomics Consortium, conducted on over 16.000 ASD individuals has been recently published [30] . The study did not show individual variants exceeding the accepted GWS threshold in the discovery dataset. However, it was able to identify a novel and genome-wide significant association on chromosome 10q24.32 (mapping in CUEDC2) in the combined metaanalysis and confirmed among top-ranking associations some of the findings from previous GWAS. 
Methods

Study Design
The 'Fondazione Smith Kline' Italy, with its "Autism Research Area", subsequently spun out as a separate Foundation ("ITAN -Italian Autism Network"), has sponsored a multi-centric project to recruit and assess autism individuals and their first-degree relatives to create a repository of genomic DNA, plasma, peripheral RNA and lymphoblastoid cell lines (LCLs). Extensive clinical data and medical history of autistic subjects and their first-degree relatives have also been stored in the database. The goal of the project is to build a biorepository that interacts with a database of extensive clinical information collected electronically at each recruiting sites, enabling genetic, genomic and proteomic research on ASD. Although the target research areas are multidisciplinary (from genetic and biomarker research, to epidemiological studies), the design of the project was driven mainly by its genetic goals. The project aims at collecting small families formed by a proband (ASD child), a sibling when available, and their parents. The collection of families would allow performing family-based genetic association studies as well as the screening of genetic variants in cases and affected and unaffected first-degree relatives. Approximately half (48%) of the patients recruited were referred by the primary care physician, 31% by a tertiary care center, and the rest by schools, or outpatient clinics.
Recruiting sites and Ethical issues.
A study protocol for the clinical assessment and sample management was written and agreed by the main centers and founding members of the network. Candidate recruiting sites were selected among clinical centers with a demonstrated ability to assess autism families as described in the project protocol. The study and its protocol were approved by the Azienda Ospedaliera Universitaria Integrata of Verona Ethic Review Board. Furthermore, each recruiting site obtained independent approval to conduct the project by their respective local ethical review committees.
Eighteen sites joined the Italian Autism Network, with thirteen actively recruiting. All adult subjects participating in this project gave their consent (or the consent for their chidren) to donate biological samples and clinical and demographic information to participate in this study; assent to participate to this study from the children was obtained whenever possible.
Subjects
Cases, parents and, whenever available, sibling and/or non-affected individuals identified as controls, were recruited. Based on the selection criteria and the family composition, different type of families can be summarized through the pedigree analysis. We used the R package kinship2 with the pedigree shrinking function to gain a metric of pedigree structure in terms of bitSize (a measure is defined as 2 * # NonFounders -# Founders, see [31] ). Non-affected siblings of less and 18 years of age recruited were assessed with medical, psychiatric and neurologic examination. For each non-affected sibling, PAX gene tubes, storing them for 2 hours at room temperature, cooling them at -20 o and later at -80 o to be ready for shipment. Samples for DNA extraction and cell lines transformation were shipped at room temperature to the biorepository on the same day of collection. Frozen samples (plasma, blood samples for RNA) were shipped via express courier in dry ice to the biorepository.
Inclusion and Exclusion Criteria
Upon delivery at the biorepository, Plasma aliquots and PAX gene tubes were stored at -80 o . DNA extraction was performed using the Puregene Blood Kit (Gentra Systems, Minneapolis, MN, US), a modified salting-out precipitation method, following the manufacturer's instructions. Each DNA sample was then quality controlled and quantified using NanoDrop ND 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, US). RNA samples from lymphocytes were isolated with QIAcube system, quantified with NanoDrop and analyzed for quality control by use of the RNA 6000 NanoLabChip (Agilent Technologies, Santa Clara, CA, US). The biorepository also transformed the lymphocytes with EBV into lines that were and then stored in Liquid Nitrogen. All relevant data regarding the samples are entered into a computerized system that allows matching the information of the samples with the clinical data stored in the centralized clinical database. 
Data security procedure for the clinical database
Recruitment progress to date.
To date, the ITAN consortium has recruited 812 subjects, i.e. 252 probands and 560 first degree relatives, for a total of 249 families. In Table 1 we provide information on the distribution of samples among recruiting centers and the demographic of the collection. In Figure 1 we illustrate the distribution of pedigree structures among families recruited in the study. Legend: Distribution of subjects among recruiting centers and summary of demographic information. *indicates centers where family recruitment is not completed (eg affected subjects less than N of families). $ Indicates centers which have recruited families with >1 affected subjects
Clinical phenotypes
The clinical assessment was derived by full neuropsychiatric evaluation and structured interviews (i.e.: ADI-R, and ADOS) by appropriately trained and certified staff. The average age at interview of the affected and non-affected subjects recruited to date is 8.89 and 11.53, respectively, while the ratio of males in the affected samples is 85.31%, reflecting the higher incidence of autism in males reported for the disease in the general population. For the non-affected siblings, the proportion of males is 55.55%. Figure 
Preliminary genetic investigations
So far, DNA samples from subjects of the ITAN collection have been utilized for testing candidate risk variants for autism derived from large GWAS investigations [26, 27, 33] . Furthermore, the regulation of candidate genes has been studied by analyzing RNA expression in LCLs from selected probands and non-affected siblings [34] . A large proportion of the discordant sibling pairs (for a total of 152 samples) was genotyped on the PsychArray (Illumina Inc., San Diego, California, USA) and 
